Yan Wang

Dr. Yan Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
YWYubo Wang
Yubo Wang
XJXinhai Jiang
Xinhai Jiang
XSXiaohan Song
Xiaohan Song
ZMZhi Jie Ma
Zhi Jie Ma
YWYan Wang
Yan Wang
Background: Diabetes-induced immune impairment and insulin resistance increase infection risk, which may progress to sepsis that further deteriorates diabetic status. Stem cell-based interventions show therapeutic potential for both diseases. This study sought to uncover common stem cell-related genes (SCRGs) between T2DM and sepsis.Methods: The GSE15932 dataset for T2DM and GSE65682 dataset for sepsis from the Gene Expression Omnibus (GEO) were utilized to locate common differentially expressed genes (DEGs), which were then intersected with SCRGs to derive shared differentially expressed SCRGs (DE-SCRGs). The stem-cell-related biomarkers were discovered through combining functional similarity analysis, machine learning algorithms, and receiver operating characteristic (ROC) curves. Subsequently, functional enrichment analysis, immune infiltration, and single-cell analyses were conducted to investigate the potential pathways by which biomarkers regulate T2DM and sepsis. Finally, the expression of biomarkers was further verified at both transcriptional and protein levels through the establishment of an in vitro model of T2DM-sepsis.Results: Through a comprehensive analysis, CAPG and DDAH2 were found and those were significantly highly expressed in both T2DM and sepsis. Analysis of functional enrichment demonstrated they were implicated in “FC gamma R-mediated phagocytosis” and “Ribosome”. Immune infiltration indicated a considerable disparity in the quantity of CD8 T cells and monocytes when comparing T2DM versus control groups, as well as sepsis versus control groups. At the cellular level, notable differences in CARG expression among alpha cells, beta cells, delta cells, and pancreatic stellate cells (PSCs) were observed in the two groups being compared. At transcription and protein levels, CAPG and DDAH2 were significantly more highly expressed in the T2DM-sepsis model than in the controls. The results corroborated the bioinformatics analysis conclusions, reinforcing the study’s validity.Conclusion: Two common stem cell-related biomarkers (CAPG and DDAH2) and their common pathways between T2DM and sepsis were discovered, providing new insights for further molecular mechanism studies.

30 December 2024 in Cancer Medicine
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
XQXin Qian
Xin Qian
YWYubo Wang
Yubo Wang
CYCaiyuan Yu
Caiyuan Yu
LFLi Feng
Li Feng
QGQiuhong Gong
Qiuhong Gong
Background: TNF‐related apoptosis‐inducing ligand (TRAIL) belongs to the tumor necrosis factor superfamily. TRAIL selectively induces apoptosis in tumor cells while sparing normal cells, which makes it an attractive candidate for cancer therapy. Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors have demonstrated safety and tolerability in clinical trials. However, they have failed to exhibit expected clinical efficacy. Consequently, extensive research has focused on optimizing TRAIL‐based therapies, with one of the most common approaches being the construction of TRAIL fusion proteins. Methods: An extensive literature search was conducted to identify studies published over the past three decades related to TRAIL fusion proteins. These various TRAIL fusion strategies were categorized based on their effects achieved. Results: The main fusion strategies for TRAIL include: 1. Construction of stable TRAIL trimers; 2. Enhancing the polymerization capacity of soluble TRAIL; 3. Increasing the accumulation of TRAIL at tumor sites by fusing with antibody fragments or peptides; 4. Decorating immune cells with TRAIL; 5. Prolonging the half‐life of TRAIL in vivo; 6. Sensitizing cancer cells to overcome resistance to TRAIL treatment. Conclusion: This work focuses on the progress in recombinant TRAIL fusion proteins and aims to provide more rational and effective fusion strategies to enhance the efficacy of recombinant soluble TRAIL, facilitating its translation from bench to bedside as an effective anti‐cancer therapeutic.

31 October 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YWYubo Wang
Yubo Wang
XSXiaohan Song
Xiaohan Song
YWYan Wang
Yan Wang
NWNan Wang
Nan Wang


25 April 2025 in Journal of Proteome Research
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
YHYanbin He
Yanbin He
XQXin Qian
Xin Qian
XZXiaoyan Zheng
Xiaoyan Zheng
YWYaya Wang
Yaya Wang
QGQiuhong Gong
Qiuhong Gong

1 January 2024 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
YWYan Wang
Yan Wang
CYCaiyuan Yu
Caiyuan Yu
XZXiaoyan Zheng
Xiaoyan Zheng
YWYaya Wang
Yaya Wang
WZWei Zhang
Wei Zhang
Dipeptidyl peptidase 4 (DPP-4) inhibitors are new antidiabetic drugs. Their effects on the respiratory system remain unclear. This study aimed to determine the association between DDP-4 inhibitors and acute respiratory failure (ARF) among patients with type 2 diabetes mellitus (T2DM). A meta-analysis was performed by searching the PubMed, Embase, and CENTRAL databases up to July 3rd, 2024, to identify randomized controlled, double-blind, and placebo controlled-cardiovascular outcomes trials (CVOTs) that enrolled participants with T2DM. A total of 6,532 studies were initially retrieved; ultimately, 5 large CVOTs enrolling 47,714 adult T2DM patients were included in the meta-analysis. Overall, there were a nonsignificant increase in the risk of ARF in the DDP-4 inhibitor group compared with the placebo group (RR, 1.72; 95% CI, 0.59 to 4.97; p = 0.319). This is the first meta-analysis to evaluate the association between DDP-4 inhibitors and ARF among T2DM patients. In general, these findings suggest that DPP-4 inhibitors may slightly, but non-significantly, increase the risk of ARF in T2DM patients. As few studies are available and few ARF events occurred, further well-designed large-scale studies need to be performed.